Publication details
Cost benefit tumor markeru SCCA v dispenzární péči pacientek s karcinomem děložního hrdla
| Title in English | Cost benefit SCCA tumor marker in the follow up of patients with squamous cell carcinoma of the cervix |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Proceedings |
| Conference | XXXVI. Brněnské onkologické dny |
| MU Faculty or unit | |
| Citation | |
| Field | Gynaecology and obstetrics |
| Keywords | tumor marker - cervical cancer - SCCA - folllow up |
| Description | SCCA is a sensitive marker of disease recurrence, especially in patients with elevated tumor markers before the primary operation. Most often manifest recurrence during the first two years after completion of primary therapy, serum positivity occurs in larger files in about 80% of relapses. Regular monitoring of patients after primary treatment of malignancy of the cervix (using a radical surgery) in well defined intervals and diagnosis of recurrence in an asymptomatic stage, but do not improve survival compared with symptomatic patients, who appear to control the clinical signs of relapse. |